

**Official FAX Transmittal****RECEIVED**  
**CENTRAL FAX CENTER**

SEP 16 2004

Application No.: 09/919,345 )  
Confirm. No.: 2746 ) Group Art Unit.: 1634  
Applicant: Boris P. ) Examiner: Frank Lu  
BELOTSERKOVSKI )  
Filing Date: 07/30/2001 )  
For: ENHANCED TARGETING OF DNA SEQUENCES BY  
RECOMBINASE PROTEIN AND SINGLE-STRANDED  
HOMOLOGOUS DNA PROBES USING DNA ANALOG  
ACTIVATION

---

To: USPTO Centralized FAX number  
Telephone: Fax: 703.872.9306

From: Daniel M. Becker, Reg. No. 38,376  
Telephone: 650.324.7014  
Direct Fax: 650.324.6665


No. of Pages: 7 (including cover)  
Date: September 16, 2004

---

**CERTIFICATE OF FACSIMILE TRANSMISSION (37 CFR 1.6(d))**

I hereby certify that this correspondence is being transmitted by facsimile on September 16, 2004 to the United States Patent and Trademark Office at the facsimile number set forth above.

Date: September 16, 2004

  
Rachel Meun

The information contained in this communication is intended only for the use of the addressee and may be confidential, may be attorney-client privileged and may constitute inside information. Unauthorized use, disclosure or copying is strictly prohibited, and may be unlawful. If you have received this communication in error or you have not received all pages, please call the sender immediately at (650) 324-7000.

Heller Ehrman White &amp; McAuliffe LLP www.hewm.com

SEP 16 2004

PTO/SB/81 (08-04)

Approved for use through 11/30/2005. OMB 0851-0035

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**POWER OF ATTORNEY  
and  
CORRESPONDENCE ADDRESS  
INDICATION FORM**

Application Number	09/919,345
Filing Date	07/30/2001
First Named Inventor	Boris P. Briniserkovskii
Title	Enhanced Targeting of DNA Sequences by Recombinant Protein and Single-Stranded Homologous DNA Probes using DNA Analog Activation
Art Unit	1634
Examiner Name	Frank Lu
Attorney Docket Number	41428-0325 001

I hereby appoint:

☒ Practitioners associated with the Customer Number:

25213

OR

☐ Practitioner(s) named below:

Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

☒ The address associated with the above-mentioned Customer Number.

OR

☐ The address associated with Customer Number:

OR

☐ Firm or Individual Name

Address

Address

City

State

Zip

Country

Telephone

Fax

I am the:

☐ Applicant/Inventor.☒ Assignee of record of the entire interest. See 37 CFR 3.71.  
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)**SIGNATURE of Applicant or Assignee of Record (If assignee, put name, title and company name in the "Name" space below)**

Name Hope Liebke, General Counsel, Genomics Division, Tapestry Pharmaceuticals, Inc.

Signature

Date

Telephone 302.286.8820

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☒ \*Total of 1 forms are submitted.

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FILES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/98 (08-04)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**STATEMENT UNDER 37 CFR 3.73(b)**Applicant/~~Patent Owner~~ Boris P. Belotserskovskii et al.Application No./~~Patent No.~~ 09/919,345Filed/Issue Date: 07/30/2001Entitled: Enhanced Targeting of DNA Sequences by Recombinase Protein and Single-Stranded Homologous DNA Probes using DNA Analog ActivationTapestry Pharmaceuticals, Inc.a corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or2. ☐ an assignee of less than the entire right, title and interest.  
The extent (by percentage) of its ownership interest is \_\_\_\_\_ %  
in the patent application/patent identified above by virtue of either:A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.**OR**B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:Boris P. Belotserskovskii; Gurucharan Reddy;David A. Zarling1. From: \_\_\_\_\_ To: Pangene CorporationThe document was recorded in the United States Patent and Trademark Office at  
Reel 012439, Frame 0130, or for which a copy thereof is attached.2. From: Pangene Corporation To: NaPro BioTherapeutics, Inc.The document was recorded in the United States Patent and Trademark Office at  
Reel 013697, Frame 0981, or for which a copy thereof is attached.3. From: NaPro BioTherapeutics, Inc. To: Tapestry Pharmaceuticals, Inc.

The document is attached hereto.

☐ Additional documents in the chain of title are listed on a supplemental sheet.☒ Copies of assignments or other documents in the chain of title are attached.

(NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Sept 13 2004  
Date302.286.6820

Telephone number

Hope Liebke

Typed or printed name

Hope Liebke  
SignatureGeneral Counsel, Genomics Division

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.